Forest biopharma & phytochemicals

01Overview and value chain#

Markers EC: EU pharma & Novel Food legislation | OECD: Biotech & health | Regulator: FDA (USA), EFSA/EMA (EU), NMPA (China)

Forest biopharma & phytochemicals is the industry that turns forest and medicinal plants into pharmaceutical actives and standardized botanical ingredients. Phyton Biotech (Germany) produces paclitaxel by plant cell fermentation rather than yew-tree harvest, advancing sustainable taxane bioproduction; Indena (Italy, founded 1921) is a long-standing botanical-extract leader with a taxane-derivative process improving paclitaxel recovery from Taxus baccata; Sabinsa (USA) won Great-Britain Novel Food authorization for its Curcumin C3 Reduct® curcuminoid; Natural Remedies (India) runs an Animal Healthcare Innovation Center around Siddha-based herbal actives for veterinary use; and Pharmactive (Spain) supplies the clinically-studied ABG10+® aged-black-garlic and affron® saffron extracts. The route spans plant sourcing, solvent extraction, phytochemical standardization and clinical-grade evidence.

The key directions of forest biopharma & phytochemicals are:

1. Taxane biosynthesis (Taxane Biosynthesis): paclitaxel and taxane API via plant cell fermentation and Taxus extraction (Phyton Biotech, Indena).
2. Botanical solvent extraction (Botanical Solvent Extraction): standardized botanical active-ingredient extraction (Indena, Pharmactive).
3. Phytochemical standardization (Phytochemical Standardization): marker-based standardization of curcuminoid/garlic/saffron actives (Sabinsa, Pharmactive).
4. Plant cell fermentation (Plant Cell Fermentation): cultivation of plant cells in bioreactors to produce forest-plant actives without harvesting the tree (Phyton Biotech).

Sectoral value chain#

[forest / medicinal plant (Taxus, Curcuma, garlic, saffron)] ──> [biomass harvest / cell culture] ──> [extraction]
                                                                       │
                                                               (purification & standardization)
                                                                       │
                                                                       ▼
[drug / supplement ingredient] <─── [clinical evidence & formulation] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Plant cell fermentation (Plant Cell Fermentation): bioreactor plant-cell cultures producing forest-plant actives without tree harvest (Phyton Biotech paclitaxel).
• Marker-based standardization (Marker-Based Standardization): quantifying marker compounds (curcuminoids, allicin, saffron crocins) for reproducible actives.
• Taxane recovery (Taxane Recovery): improved Taxus paclitaxel recovery processes (Indena taxane-derivative patent).

02US#

The United States contributes curcumin and botanical-ingredient standardization plus the FDA botanical-drug pathway.

Sabinsa, FDA botanical drug guidance#

• Sabinsa: developed Curcumin C3 Reduct® curcuminoids and secured Great-Britain Novel Food authorization, advancing standardized turmeric phytochemicals for the nutrition market.
• FDA botanical guidance: the FDA botanical drug development pathway frames US approval of plant-derived therapeutics.
• Standardization base: US botanical-ingredient firms anchor marker-based standardization for supplement and drug use.

03CN#

China’s traditional-medicine heritage anchors a large plant-derived pharma base, though corporate-specific 2026 facts were not pursued in this batch.

Traditional Chinese Medicine phytochemical base#

• TCM phytochemical base: China’s traditional-medicine industry supplies a large volume of plant-derived phytochemical actives (artemisinin, paclitaxel precursors, ginsenosides) under NMPA oversight and WHO traditional-medicine frameworks.
• Caveat: this batch did not draft a specific Chinese firm candidate; the CN block is qualitative.
• Regulatory frame: NMPA governs plant-derived drugs and traditional-medicine products in China.

04EU#

Europe is the global anchor for botanical-extract API and taxane bioproduction.

Phyton Biotech, Indena, Pharmactive#

• Phyton Biotech (Germany): produces paclitaxel by plant cell fermentation, advancing sustainable taxane bioproduction that decouples the API from yew-tree harvest.
• Indena (Italy, founded 1921): a long-standing botanical-extract leader with a taxane-derivative process improving paclitaxel recovery from Taxus baccata.
• Pharmactive (Spain): supplies clinically-studied ABG10+® aged-black-garlic and affron® saffron phytochemical extracts for the supplement market.
• EU pharma & Novel Food: EU pharmaceutical legislation and the Novel Food framework frame European plant-derived drugs and botanical ingredients.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack pairs plant sourcing and extraction with phytochemical standardization and clinical-grade evidence.

1. Taxane biosynthesis (Taxane Biosynthesis):
   • Phyton Biotech grows Taxus plant cells in fermenters to produce paclitaxel without harvesting yew trees; Indena improves Taxus baccata paclitaxel recovery via its taxane-derivative process.
2. Botanical solvent extraction (Botanical Solvent Extraction):
   • Indena and Pharmactive extract standardized botanical actives (taxanes, aged-black-garlic allicin, saffron crocins) for pharma and supplement use.
3. Phytochemical standardization (Phytochemical Standardization):
   • Sabinsa and Pharmactive standardize marker compounds (curcuminoids, ABG10+ markers) to reproducible clinical-grade actives, supported by Novel Food and clinical substantiation.

07Value chains and production pipelines#

Industrial pipeline of forest phytochemicals (FDA / EU pharma / NMPA frameworks)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Plant sourcing         │ ───> │ 2. Extraction             │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Standardization        │ <─── │ 3. Purification           │
└───────────────────────────┘      └───────────────────────────┘
               │
               ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Clinical evidence      │ ───> │ 6. Formulation            │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Plant sourcing

Forest or medicinal plants (or plant cell cultures) supply the botanical feedstock; the output is raw botanical biomass or a cell-culture harvest.

Stage 2: Extraction

The biomass is solvent-extracted (or the cell culture harvested) to recover the crude active fraction; the output is a crude extract.

Stage 3: Purification

The crude extract is purified toward the phytochemical active of interest; the output is a purified active.

Stage 4: Standardization

The active is marker-standardized to a reproducible clinical-grade phytochemical API or ingredient; the output is a standardized active.

Stage 5: Clinical evidence

The standardized active is substantiated with clinical/analytical evidence (e.g. Pharmactive ABG10+ fingerprinting); the output is an evidence dossier.

Stage 6: Formulation

The active is formulated into drug or supplement dosage forms under FDA / EU pharma / NMPA frameworks; the output is a marketable forest-phytochemical product.